Faster drug-susceptibility testing for drug-resistant tuberculosis
Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas
['FUNDING_R01'] · OHIO STATE UNIVERSITY · NIH-11453734
Developing a faster, low-cost test to identify which antibiotics will work for people with drug-resistant tuberculosis, usable near clinics in high-burden areas.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | OHIO STATE UNIVERSITY (nih funded) |
| Locations | 1 site (Columbus, UNITED STATES) |
| Trial ID | NIH-11453734 on ClinicalTrials.gov |
What this research studies
If I have suspected or confirmed drug-resistant TB, this project aims to speed up lab testing that shows which drugs will kill my TB. Current culture-based tests can take weeks to months, but the team plans to develop a next-generation phenotypic test that returns results much faster and is affordable for low-resource settings. Researchers will refine laboratory methods and test them on patient samples collected at clinics, comparing the new test to standard methods. The goal is a simple, near-point-of-care test so I can start the right treatment sooner.
Who could benefit from this research
Good fit: People with confirmed or suspected tuberculosis—especially those suspected to have drug-resistant TB and who receive care at clinics in high-burden or resource-limited settings—would be ideal candidates to provide samples or participate.
Not a fit: People without TB, those with latent TB infection, or patients whose infections are sensitive to standard first-line drugs may not directly benefit from this specific test development.
Why it matters
Potential benefit: If successful, patients could get the correct TB drugs much sooner, reducing treatment delays, spread of infection, and risk of death.
How similar studies have performed: Rapid genotypic tests like GeneXpert are fast and widely used, but rapid phenotypic methods are less common and this project builds on promising early lab methods to deliver a practical alternative.
Where this research is happening
Columbus, UNITED STATES
- OHIO STATE UNIVERSITY — Columbus, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TORRELLES, JORDI B — OHIO STATE UNIVERSITY
- Study coordinator: TORRELLES, JORDI B
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Communicable Diseases